Background: Based on the microRNA (miRNA) signature of bladder cancer (BC) by deep sequencing, we recently found that several double-stranded mature miRNAs derived from the same pre-miRNAs were sufficiently expressed and acted as tumour suppressors by regulating common target genes in BC. Our deep-sequencing signature of BC showed that all miR-199 family members (miR-199a-3p/-5p and miR-199b-3p/-5p) were also downregulated. We hypothesised that these miRNAs may function as tumour suppressors by regulating common target genes.
Bladder cancer (BC) is the ninth most commonly diagnosed cancer worldwide in 2012 (Torre et al, 2015; Antoni et al, 2017) . In the United States of America, it was estimated that B76 960 cases were diagnosed and 16 390 patients died in 2016 . Bladder cancer can be classified into two groups: non-muscleinvasive BC (NMIBC) and muscle-invasive BC (MIBC). More than 70% of patients with BC are diagnosed with NMIBC . However, patients with NMIBC tend to have a high rate of recurrence, as high as 50-70% (Kaufman et al, 2009) . Patients with localised MIBC are managed by radical cystectomy. However, despite potential curative surgery, B50% of patients develop metastatic disease within only 2 years (Sternberg et al, 2013) . Patients with advanced BC are generally treated with systemic combination chemotherapy of cisplatin and gemcitabine; however, the therapeutic effects are insufficient (Kaufman et al, 2009; Sternberg et al, 2013) . Most clinical trials of chemotherapeutics with other drugs for advanced BC have shown limited benefits and a short median survival period of only B9.3-15.8 months De Santis et al, 2012) . Moreover, there are no more reliable markers other than urine cytology for BC diagnosis, and this approach has relatively low sensitivity (30-40%) . Therefore, novel prognostic markers and effective treatment strategies based on RNA network studies are urgently needed to improve outcomes in patients with BC.
MicroRNAs (miRNAs) are endogenous small noncoding RNAs of 19-22 nucleotides in length that negatively regulate protein-coding genes by binding to the 3 0 -untranslated region (UTR) of the target mRNA, thereby inhibiting transcriptional or post-transcriptional expression (Bartel, 2004; Carthew and Sontheimer, 2009) . Previous studies have demonstrated that miRNAs are aberrantly expressed in various types of cancer and have the critical roles in cancer cell behaviour (Di Leva and Croce, 2010) . Therefore, the detection of aberrantly expressed miRNAs and their target genes could provide important insights into the elucidation of miRNAmediated oncogenic pathways.
In miRNA biogenesis, the guide-strand of miRNA integrates into the RNA-induced silencing complex (RISC), whereas the passenger strand is inactivated through degradation (Chendrimada et al, 2007; Carthew and Sontheimer, 2009 ). However, our previous analysis of miRNA signatures in BC by deep sequencing revealed that the opposite strands of miR-144-5p/-3p, miR-145-5p/-3p, and miR-139-5p/-3p function as dual-strand tumour-suppressor miRNAs (Matsushita et al, 2015 Yonemori et al, 2016) . Based on our additional analysis of the miRNA signature, we also found another set of downregulated miRNAs, the miR-199 family (miR199a-3p/-5p derived from pre-miR-199a-1/-2 and miR-199b-3p/-5p derived from pre-miR-199b) (Itesako et al, 2014) . The sequence of miR-199a-3p (guide strand) is the same as that of miR-199b-3p (guide strand), and the sequence of miR-199a-5p (passenger strand) is very similar to that of miR-199b-5p (passenger strand) (only two bases differ). Therefore, we hypothesised that these miRNAs may function as tumour suppressors by regulating common target genes. Several previous studies have shown that miR-199 family members function as tumour suppressors in various types of cancer Li et al, 2015; Sun et al, 2016) . With regard to miR-199a-5p, some reports have shown that this miRNA functions as a tumour suppressor in BC (Su et al, 2013; Song et al, 2015) . However, the role of miR-199 family members in BC is still unclear.
The aim of this study was to investigate the antitumour effects of miR-199 family members and to determine their regulatory targets in BC. The elucidation of molecular targets regulated by tumour-suppressive miR-199 family member will provide important new insights into the potential mechanisms of BC oncogenesis and progression.
MATERIALS AND METHODS
Clinical specimens and cell culture. The tissue specimens for quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR) were collected from BC patients (n ¼ 32) at Kagoshima University Hospital between 2004 and 2013. Normal bladder epithelia (NBE) (n ¼ 12) were derived from patients with noncancerous disease. The specimens were staged according to the American Joint Committee on Cancer-Union Internationale Contre le Cancer tumour node metastasis classification and histologically graded (Sobin and Compton, 2010) . Our study was approved by the Bioethics Committee of Kagoshima University; written prior written consent and approval were obtained from all patients. Patient details and clinicopathological characteristics are summarised in Supplementary Table 1. We used human BC cell lines: T24 and BOY. These cell lines were described in our previous studies (Itesako et al, 2014) .
Tissue collection and RNA extraction. Tissues were immersed in RNA later (Thermo Fisher Scientific, Waltham, MA, USA) and stored at À 20 1C until RNA extraction. Total RNA, including miRNA, was extracted using a mirVana miRNA Isolation Kit (Thermo Fisher Scientific) following the manufacturer's protocol.
Quantitative real-time reverse transcription-polymerase chain reaction. Stem-loop RT-PCR (TaqMan MicroRNA Assays; P/N: 000498 for miR-199a-5p, P/N: 000500 for miR-199b-5p, and P/N: 002304 for miR-199a-3p/miR-199b-3p; Applied Biosystems, Foster City, CA, USA) was used to quantify miRNAs according to previously published conditions (Ichimi et al, 2009) . We used human RNU48 (P/N: 001006; Applied Biosystems) as an internal control, and the DCt method was used to calculate the fold changes. As for integrin a3 (ITGA3), we applied a SYBR-green quantitative PCR-based array approach; each sequence is listed in Supplementary Table 2. The experimental procedures followed the protocol recommended by the manufacturer. Quantitative realtime reverse transcription-polymerase chain reaction was performed with 500 ng of total RNA using Power SYBR Green Master Mix (cat. no. 4367659; Applied Biosystems) on a 7300 Real-time PCR System (Applied Biosystems). The specificity of amplification was monitored using the dissociation curve of the amplified product. All data values were normalised to GUSB, and the DCt method was used to calculate the fold change.
Transfection with mature miRNA and siRNA. As described elsewhere (Ichimi et al, 2009 ), T24 and BOY cells were transfected with Lipofectamine RNAiMAX transfection reagent (Thermo Fisher Scientific) and Opti-MEM (Thermo Fisher Scientific) with 10 nM mature miRNA or small interfering RNA (siRNA). Mature miRNA precursors (hsa-miR-199a-5p, product ID PM10893; hsamiR-199b-5p, product ID: PM10553; hsa-miR-199a/b-3p, product ID: PM11779; Thermo Fisher Scientific) and negative-control miRNA (product IDs: AM17110, AM17111; Thermo Fisher Scientific) were used in gain-of-function experiments, whereas ITGA3 siRNA (cat nos. HSS105529 and HSS105531; Thermo Fisher Scientific) and negative-control siRNA (D-001810-10; Thermo Fisher Scientific) were used in loss-of-function experiments.
Cell proliferation, migration, and invasion assays. Cell proliferation was determined by XTT assay according to the manufacturer's instructions. Cell migration activity was evaluated with wound-healing assays. Cell invasion assays were performed using modified Boyden chambers consisting of Transwell-precoated Matrigel membrane filter inserts with 8-mm pores in 24-well tissue culture plates (BD Biosciences, Bedford, MA, USA). The experimental procedures were performed as described in our previous studies Yoshino et al, 2011) . All experiments were performed in triplicate.
Western blot analysis. After transfection (72 h), protein lysates were separated on NuPAGE on 4-12% Bis-Tris gels (Invitrogen, Carlsbad, CA, USA) and transferred to PVDF membranes. Immunoblotting was carried out with diluted (1 : 1000) anti-ITGA3 antibodies (HPA008572; Sigma-Aldrich, St Louis, MO, USA) and anti-b-actin antibodies (bs-0061R; Bioss, Woburn, MA, USA). Specific complexes were visualised using an echochemiluminescence detection system (GE Healthcare, Little Chalfont, UK) as described previously .
Immunohistochemical analysis. A tissue microarray of BC samples was obtained from US Biomax Inc. (product ID: BL 1002; Rockville, MD, USA). Detailed information on all tumour specimens can be found at http://www.biomax.us/index.php. The tissue microarray was immunostained following the manufacturer's protocol with an Ultra Vision Detection System (Thermo Scientific). Primary rabbit polyclonal antibodies against ITGA3 (HPA008572; Sigma-Aldrich) were diluted 1 : 20. Immunostaining was evaluated according to the scoring method described previously . Each case was scored on the basis of the intensity and area of staining. The intensity of staining was graded on the following scale: 0, no staining; 1 þ , mild staining; 2 þ , moderate staining; and 3 þ , intense staining. The area of staining was evaluated as follows: 0, no staining of cells in any microscopic field; 1 þ ,o30% of cells stained positive; 2 þ , 30-60% stained positive; 3 þ ,460% stained positive. The immunostaining scores (intensity þ extent) were combined and analysed. All samples were independently scored by two of the authors (T Sakaguchi and K Miyamoto), who were blinded to the patient status.
In silico analysis for the identification of genes regulated by miR-199a-3p/-5p and miR-199b-3p/-5p. To obtain candidate target genes regulated by miR-199a-3p/-5p and miR-199b-3p/-5p, we used TargetScan database Release 7.0 (http://www.targetscan.org). These candidate target genes data were adapted to the KEGG pathway categories by the GENECODIS program (http://genecodis.cnb.csic.es). Additionally, the Gene Expression Omnibus (GEO) database (accession numbers: GSE11783 and GSE31684) was used to identify upregulated genes in BC specimens.
Plasmid construction and dual-luciferase reporter assays. Partial wild-type sequences of the 3 0 -UTR of ITGA3 or sequences with deletion of the miR-199a-5p/miR-199b-5p target sites and miR199a-3p/miR-199b-3p target site were inserted between the XhoI and PmeI restriction sites in the 3 0 -UTR of the hRluc gene in the psiCHECK-2 vector (C8021; Promega, Madison, WI, USA). T24 and BOY cells were transfected with 50 ng vector and 10 nM miR199a-5p or miR-199b-5p or miR-199a/b-3p. The procedure for dual-luciferase reporter assay was described previously (Yoshino et al, 2013a) .
Analysis of the BC cohort in TCGA data sets. The Cancer Genome Atlas (TCGA) cohort database was used to analyse ITGA3 mRNA expression levels in normal and BC samples and to determine if there was a clinical relationship between miR199a/b or ITGA3 expression and overall survival. RNA-seq expression data (normalised RSEM) and miRNA-seq data (reads per million mapped reads) were used for gene and miRNA quantification (Li and Dewey, 2011) . mRNA expression by whole-exome sequencing data was available for 408 patients with BC. Full sequencing information and clinical information were acquired using cBioPortal (http://www.cbioportal.org/ public-portal/) and TCGA (https://tcga-data.nci.nih.gov/tcga/) (Cerami et al, 2012; Gao et al, 2013; Cancer Genome Atlas Research N, 2014) . This study meets the publication guidelines provided by TCGA (http://cancergenome.nih.gov/publications/ publicationguidelines).
Statistical analysis. The relationships between two groups were analysed using Mann-Whitney U-tests. The relationships between three variables and numerical values were analysed using Bonferroni-adjusted Mann-Whitney U-tests. Spearman's rank tests were used to evaluate the correlations between the expression of miR-199a-5p or miR-199b-5p and miR-199a/b-3p. w 2 tests were used to analyse the relationships between ITGA3 expression in Immunohistochemical (IHC) staining and clinicopathological characteristics. The overall survival of patients with BC from the TCGA cohort was evaluated by the Kaplan-Meier method. Patients were divided into two or three groups based on the number of patients in the cohort, and differences between the two groups were evaluated by log-rank tests. All analyses were carried out using Expert StatView software, version 5.0 (Cary, NC, USA). -199a-5p, miR-199b-5p , and miR-199a/ b-3p in BC. First, we evaluated the expression levels of miR-199a-5p, miR-199b-5p, and miR-199a/b-3p in BC tissues (n ¼ 32) and NBE (n ¼ 12) by qRT-PCR. The expression levels of these mature miRNAs were significantly reduced in BC tissues compared with those in the NBE (P ¼ 0.0032, Po0.0001, and Po0.0001, respectively; Figure 1A ). Spearman's rank test revealed significant positive correlations between the expression levels of these miRNAs (each Po0.0001; Figure 1B ). We found no significant relationships between the clinicopathological parameters (i.e., -199a-5p, miR-199b-5p , and miR-199a/b-3p, as determined by qRT-PCR, were significantly lower in BC specimens than in NBE specimens (P ¼ 0.0032, Po0.0001, and Po0.0001, respectively). (B) Spearman's rank test demonstrated that these miRNAs expression levels were positively correlated (each Po0.0001).
RESULTS
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miR-199 family regulates ITGA3 in bladder cancertumour stage, grade) and the expression levels of miR-199a-5p, miR-199b-5p, and miR-199a/b-3p (data not shown).
Effects of miR-199a-5p, miR-199b-5p, and miR-199a/b-3p restoration on cell proliferation, migration, and invasion activities in BC cell lines. We performed gain-of-function studies using T24 and BOY cells transfected with miR-199a-5p, miR-199b-5p, or miR-199a/b-3p to investigate their functional roles. XTT assays revealed significant inhibition of cell proliferation in T24 and BOY cells transfected with miR-199a-5p, miR-199b-5p, and miR-199a/b-3p in comparison with mock or miR-control transfectants (T24: Po0.05, P ¼ 0.0007, and Po0.0001, respectively; BOY: Po0.0001, Po0.0001, and Po0.05, respectively; Figure 2A ). Moreover, wound-healing assays demonstrated that cell migration activity was significantly inhibited in these miRNA transfectants in comparison with that in mock or miR-control transfectants (each Po0.0001; Figure 2B ). Finally, Matrigel invasion assays demonstrated that the number of invading cells was significantly decreased in these miRNA transfectants compared with mock or miR-control transfectants (each Po0.0001; Figure 2C ). These data suggested that miR-199 family members functioned as tumour suppressors in BC cells.
Identification of common target genes regulated by miR-199 family members in BC cells. Next, in silico analysis was used to gain additional insights into the molecular mechanisms and pathways regulated by tumour-suppressive miR-199 family members in BC cells. Supplementary Figure 1 shows our strategy to narrow down the common target genes of miR-199 family members. Candidate genes of miR-199-5p and miR-199-3p (4195 and 3013 genes, respectively) were identified using TargetScan database Release 7.0 (http://www.targetscan.org). Among these candidate genes, we identified 1127 common candidate target genes of miR-199-5p and miR-199-3p. Moreover, these candidate target genes were categorised into KEGG pathways using GENECODIS analysis (http://genecodis.cnb.csic.es). Our analysis indicated that these genes were implicated in 64 significantly enriched pathways (Supplementary Table 3 ). Among these pathways, we focused on 'pathways in cancer', because the greatest number of genes (29 genes) was listed within this pathway. Of these 29 genes, 10 genes were upregulated in the GEO database (accession numbers: GSE11783 and GSE31684; Supplementary  Table 4) . Finally, among these 10 genes, we focused on the ITGA3 gene because miR-199 family members significantly inhibited cancer cell migration and invasion. Molecular target searches suggested that ITGA3 was a promising candidate target regulated by the miR-199 family in BC cells.
ITGA3 was directly regulated by miR-199a-5p, miR-199b-5p, and miR-199a/b-3p in BC cells. We performed qRT-PCR and western blot analyses to confirm that restoration of miR-199a-5p, miR199b-5p, and miR-199a/b-3p downregulated ITGA3 mRNA expression in T24 and BOY cells. ITGA3 mRNA levels were markedly and significantly reduced in these miRNA transfectants in comparison with those in mock or miR-control transfectants (Po0.0001 and P ¼ 0.0002; Figure 3A) . Moreover, the expression 199a-5p miR-199a-5p miR-199a-5p miR199b-5p miR-199b-5p miR-199b-5p miR199a/b-3p miR-199a/b-3p miR-199a/b-3p of ITGA3 protein was markedly repressed in these miRNAs transfectants in comparison with mock or miR-control transfectants ( Figure 3B ). Two bands were observed on western blots and were found at the expected sizes for ITGA3 at around 130 kDa. These two bands could be the two isoforms of ITGA3 (a3A and a3B) (de de Melker et al, 1997). Another possibility is that aberrantly modified ITGA3 may be expressed. In fact, the expression of aberrantly glycosylated ITGA3 in BC has been reported (Li et al, 2014 (Li et al, , 2016a .
We then performed dual-luciferase reporter assays in BC cells to determine whether ITGA3 was directly regulated by these miRNAs. The TargetScan database predicted that there were two binding sites for miR-199a/b-5p (positions 395-401 and 421-426) and one binding site for miR-199a/b-3p (position 439-452) in the ITGA3 3 0 -UTR. We used vectors encoding the partial wild-type sequence of the 3 0 -UTR of ITGA3, including the predicted miR-199a/b-5p and miR-199a/b-3p target sites. We found that the luminescence intensity was significantly reduced by co-transfection with these miRNAs and the vector carrying the wild-type sequences at positions 395-401 and 439-452 in the ITGA3 3 0 -UTR (each Po0.0001), whereas transfection with the deletion vector (in which the binding site had been removed) and the wild-type sequence at positions 421-426 in the ITGA3 3 0 -UTR blocked the decrease in luminescence ( Figure 3C ). These data suggested that miR-199a/b-5p and miR-199a/b-3p were directly bound to specific sites in the 3 0 -UTR of ITGA3 mRNA.
Effects of ITGA3 knockdown on cell proliferation, migration, and invasion in BC cell lines. To investigate the functional role of ITGA3 in the BC cells, we performed loss-of-function studies using cells transfected with two si-ITGA3 constructs (si-ITGA3_1 and si-ITGA3_2). We evaluated the knockdown efficiency of si-ITGA3 transfection in BC cells. Quantitative real-time reverse transcriptionpolymerase chain reaction and western blot analyses showed that these siRNAs effectively downregulated ITGA3 mRNA and protein expression in both cell lines (each Po0.0001; Figures 4A and B) . Additionally, in this experiment, we also observed two bands on western blot analysis for ITGA3, similar to the results described in the previous section. XTT assays demonstrated that BOY cell proliferation was inhibited in si-ITGA3 transfectants in comparison with that in mock or si-control transfectants (each Po0.0001). Although si-ITGA3_1 inhibited cell proliferation significantly in T24 cells, no significant inhibition was observed in si-ITGA3_2-transfected T24 cells ( Figure 4C ). In contrast, wound-healing assays demonstrated that cell migration activity was significantly inhibited in si-ITGA3 transfectants in comparison with that in mock or si-control 
Figure 3. Direct regulation of ITGA3 by miR-199a/b-5p and miR-199a/b-3p. (A) The expression of ITGA3 mRNA was significantly repressed in these miRNAs transfectants in comparison with that in mock or miR-control transfectants. GUSB was used as an internal control. *P ¼ 0.0002; **Po0.0001. (B) The expression of ITGA3 protein was markedly repressed in these miRNAs transfectants in comparison with that in mock or miRcontrol transfectants. b-Actin was used as a loading control. (C) Dual-luciferase reporter assays using vectors encoding putative miRNA target sites for wild-type or deleted regions. Normalised data were calculated as ratios of Renilla/firefly luciferase activities. The luminescence intensity was significantly reduced by co-transfection with miR-199a/b-5p or miR-199a/b-3p and the vector carrying the wild-type sequences at positions 395-401 and 439-452 in the ITGA3 3 0 -UTR. *Po0.0001, **P ¼ 0.0001.
miR-199 family regulates ITGA3 in bladder cancer BRITISH JOURNAL OF CANCER transfectants (each Po0.0001; Figure 4D ). Moreover, Matrigel invasion assays demonstrated that cell invasion activity was significantly inhibited in si-ITGA3 transfectants in comparison with that in mock or si-control transfectants (each Po0.0001; Figure 4E ).
IHC analysis of ITGA3 in a tissue microarray. Next, we examined the expression level of ITGA3 in BC specimens by IHC staining. ITGA3 was strongly expressed in several tumour lesions, whereas low expression was observed in the normal tissue ( Figures 5A-D) . Tissue microarray analysis revealed that the IHC score of tumours was significantly higher than that of normal tissues (Mann-Whitney U-test; P ¼ 0.0038, w 2 test; Po0.0001; Figure 5E , upper and Supplementary Table 5 ). In addition, we also found that ITGA3 expression in T2 or greater BCs was significantly higher than that in T1 BCs (P ¼ 0.048; Figure 5E , lower). However, we found no significant difference between the ITGA3 expression score and other pathological parameters (histological grade and pathological diagnosis) of BC patients (Supplementary Table 5 ).
Analysis of the clinical BC specimens in TCGA data sets. We investigated ITGA3 mRNA expression levels and the correlations between pre-miR-199 family members and ITGA3 expression in BC samples using the TCGA database. Among the BC cohort in TCGA, we investigated patients for whom ITGA3 expression data could be obtained. The expression level of ITGA3 was significantly upregulated in patients with BC (n ¼ 408) compared with that in normal patients (n ¼ 19; P ¼ 0.0063; Figure 6A ). Specifically, there was a significant negative correlation between miR-199a-1 or miR-199a-2 or miR-199b and ITGA3 expression (P ¼ 0.0099, R ¼ À 0.128; P ¼ 0.0189, R ¼ À 0.117; and P ¼ 0.033, R ¼ À 0.106, respectively; Figure 6B) .
We examined the correlation of pre-miR-199 family expression levels with overall survival using the TCGA database. Among the BC cohort in TCGA, we investigated 404 patients for whom pre-miR-199 family expression and survival time data could be obtained. The cohort was divided into two groups based on the number of patients. Importantly, we found that patients with low miR-199 family expression (n ¼ 202) had poor survival compared with patients with high miR-199 family expression (n ¼ 202). Kaplan-Meier analysis showed that the low miR-199a-1, miR199a-2, and miR-199b expression groups had significantly lower overall survival rates than patients with high expression of these pre-miRNA groups. The median overall survival times were 8. 46, 8.46, and 8.48 months in the low miR-199a-1, miR-199a-2, and miR-199b expression groups versus 11.44, 11.44, and 11.41 months in the high expression groups (P ¼ 0.0028, P ¼ 0.0020, and P ¼ 0.0023, respectively; Figure 6C ). Next, we examined the correlation of ITGA3 expression level with overall survival. Among the BC cohort in TCGA, we investigated 403 patients for whom ITGA3 expression and survival time data could be obtained. The cohort was divided into three groups according to the number of patients. Kaplan-Meier analysis showed that patients in the high ITGA3 expression group (n ¼ 134) exhibited lower overall survival rates compared with those in the low expression group (n ¼ 134); however, this difference was not significant (P ¼ 0.0823). Moreover, there were no significant differences between the medium ITGA3 expression group (n ¼ 135) and the high or low expression groups (Supplementary Figure 2) .
DISCUSSION
MicroRNAs are vitally important regulators that contribute to numerous physiological processes, such as cell proliferation, differentiation, development, and apoptosis (Croce, 2009; Di Leva and Croce, 2010) . MicroRNAs are unique in their ability to regulate multiple protein-coding genes. Recently, bioinformatics predictions have indicated that miRNAs may regulate more than 60% of the protein-coding genes in the human genome (Friedman et al, 2009) . Additionally, in human cancer, miRNAs are aberrantly expressed and have important roles in cancer initiation, development, and metastasis (Nelson and Weiss, 2008; Yoshino et al, 2013b) . Many genome-wide miRNA expression signatures, including deep-sequencing analysis, have revealed aberrantly upregulated or downregulated expression of miRNAs in BC (Han et al, 2011; Chen et al, 2013) . Subsequently, many studies have demonstrated that aberrantly downregulated miRNAs can function as tumour suppressors by regulating different target genes and cancer pathways. Therefore, identification of tumour-suppressive miRNAs and the molecular pathways mediated by these miRNAs is important to improve our understanding of cancer mechanisms.
In general, the guide-strand RNA from duplex miRNA is retained for direct recruitment of the RISC to target mRNAs, whereas the passenger-strand RNA is degraded (Chendrimada et al, 2007; Carthew and Sontheimer, 2009 ). In our previous study of PCR-based miRNA screening in BC, only miR-199a-5p and miR-199b-5p were indicated as downregulated miRNAs . However, in the present study, deep-sequencing analysis showed that all miR-199 family members (miR-199a-3p/-5p and miR-199b-3p/-5p) were downregulated in BC tissues in comparison with normal bladder tissues. In addition, in our other studies of deep-sequencing analysis, we also found that some passenger strands were not degraded and acted as tumour suppressors (Matsushita et al, 2016; Yonemori et al, 2016) . Thus, deep-sequencing analysis seemed to be superior to array-and miR-199 family regulates ITGA3 in bladder cancerPCR-based methods and is likely to become the gold standard for comprehensive miRNA analysis in cancer genomics . The molecular mechanism of how miR-199 family members are downregulated in BC remains unclear. However, a recent study demonstrated that the RNA-binding protein HuR, also known as ELAVL1 suppresses the maturation of miR-199a in hepatocellular carcinoma . ELAVL1 mRNA expression level was significantly upregulated in BC samples compared with normal bladder samples in TCGA database (Supplementary Figure 3A) . Moreover, there was a significant negative correlation between miR-199 family and ELAVL1 expression (Supplementary Figure 3B) . These data suggested that ELAVL1 expression might be responsible for the downregulation of miR-199 family in BC. Further studies are necessary to determine this mechanism.
miR-199 family members have been shown to have strong anticancer effects in several types of cancer, including breast cancer, colorectal cancer, and thyroid cancer, through the regulation of oncogene Li et al, 2015; Sun et al, 2016) ; however, few studies have examined these miRNAs in BC. Some few previous studies have suggested that miR-199a-5p functions as a tumour suppressor in BC. Song et al (2015) reported that miR-199a-5p functions as a tumour suppressor by regulating MLK3/NF-kB pathway. However, the roles of miR-199a-3p and miR-199b-3p/-5p in BC remain unknown. Thus, in this study, we revealed, for the first time, that miR-199 family members (miR199a-3p/-5p and miR-199b-3p/-5p) functioned as tumour-suppressive miRNAs in BC. Interestingly, several previous reports showed that elevated miR-199a levels were associated with improved survival in patients with diffuse large B-cell lymphoma (Troppan et al, 2015) and patients with breast cancer (Li et al, 2016b) . Furthermore, another report demonstrated that a panel of eight miRNAs, including miR-199a, may be a useful biomarker for predicting survival in BC (Zhou et al, 2015) . Notably, in our present study using the TCGA data set, we revealed that patients with low expression of miR-199a or miR-199b exhibited poorer overall survival than patients with high expression of these miRNAs. Therefore, we speculated that these miRNAs may be effective prognostic markers in patients with BC. However, despite the observed significant correlations between miR-199 family members and survival, our data did not reveal any significant correlations between ITGA3 and survival. This discrepant Negative correlations between ITGA3 expression and miR-199a-1, miR-199a-2, and miR-199b expression in BC tissues (P ¼ 0.0099, R ¼ À 0.128; P ¼ 0.0189, R ¼ À 0.117; and P ¼ 0.033, R ¼ À 0.106, respectively). (C) Overall survival was significantly prolonged in patients with high miR-199a-1, miR-199a-2, and miR-199b expression compared with that in patients with low expression of these miRNAs (P ¼ 0.0028, P ¼ 0.0020, and P ¼ 0.0023, respectively). observation may be explained by the fact that miR-199 family members have many target genes that influence patient prognosis in addition to ITGA3. Therefore, there may not be any correlations between ITGA3 expression and survival in patients with BC. Future studies are needed to identify other target genes of miR-199 family members.
We performed in silico analysis and finally obtained 10 candidate target genes of miR-199 family. E2F3 was at the top of the list (Supplementary Table 4) , and TCGA database also showed higher E2F3 mRNA expression in BC samples than that of normal bladder samples (Supplementary Figure 4A) . In general, E2F3 is critical for G1/S transition and has major roles in regulating tumour cell proliferation (Humbert et al, 2000) . However, in this study, we could not find strong efficacy of inhibiting cell proliferation in the miR-199s transfectants as compared with that of inhibiting cell migration or invasion. In terms of KLK3 and SLC2A1, TCGA database showed no significant differences in their mRNA expressions between BC and normal bladder samples. (Supplementary Figures 4B and C) . Therefore, we focused on ITGA3 as the candidate target of miR-199 family even though it was the fourth position on the list.
Nonetheless, our findings also demonstrated that ITGA3 has important roles in BC cell progression and may be a molecular target for BC treatment. Integrins are heterodimeric transmembrane receptors that mediate adhesion to the extracellular matrix (ECM) and immunoglobulin superfamily molecules (Desgrosellier and Cheresh, 2010) . Integrin heterodimers are formed by the combination of a-and b-subunit. Many different integrin heterodimers can be expressed on a single cell, and each can interact with multiple intracellular signalling cascades (Goodman and Picard, 2012) . Integrin a3 and b1-subunits have been identified as laminin-binding receptors, for example, laminin-5 and laminin-10/-11 (Kreidberg et al, 1996) . Extracellular matrix proteins, such as collagen, laminin, and fibronectin, regulate tissue homeostasis, organ development, inflammation, and diseases, such as cancer . Integrins are essential for cell migration and invasion, because they directly mediate adhesion to these ECM proteins (Hood and Cheresh, 2002) . Therefore, aberrant expression of ITGA3 results in promoting cancer cell migration and invasion. The Cancer Genome Atlas database analysis revealed that ITGA3 mRNA expression in BC was significantly upregulated. However, mRNA expression of integrin b1 (ITGB1) that compose integrin a3b1 heterodimer with ITGA3 was not significantly changed between BCs and normal bladder tissues (Supplementary Figure 4D) . Our speculation is that ITGA3 composes integrin a3b1 heterodimer only with ITGB1. On the other hand, ITGB1 composes many integrin heterodimers with integrin a1-2, a4-11, and aV as well as ITGA3 (Jin and Varner, 2004) . The Cancer Genome Atlas database revealed that the mRNA expression levels of these integrin a-subunits, except for ITGA3, were either not significantly changed or significantly downregulated in BCs compared with normal bladder tissues (Supplementary Figure 5) . These facts imply that total expression of ITGB1 in BC cells might balance out because of the low expression of other integrin a-subunits that bind to ITGB1. Overexpression of ITGA3 has been reported in various human cancers, such as prostate cancer, breast cancer, glioma, and oral squamous cell carcinoma (Ghosh et al, 2006; Nakada et al, 2013; Shirakihara et al, 2013; Kurozumi et al, 2016) . Ghosh et al (2006) showed that decreased integrin a3b1 expression was consistent with lower invasive tumour behaviour. Moreover, several studies have shown that ITGA3 is involved in cancer progression, cell migration, metastasis, and invasiveness in BC (Litynska et al, 2002; Mitsuzuka et al, 2005; Pochec et al, 2006; Behnsawy et al, 2011; Li et al, 2014 Li et al, , 2016a . Li et al (2014 Li et al ( , 2016a reported that aberrantly glycosylated integrin a3b1 is a new biomarker of BC and that a monoclonal antibody against this integrin heterodimer has potent antitumour activities in BC. Additionally, ITGA3 has been suggested to have a major role in modulation of other integrin receptors in BC (Litynska et al, 2002) . Interestingly, another report showed that ITGA3 expression was significantly associated with the incidence of intravesical recurrence after TURBT (Behnsawy et al, 2011) . A recent report showed that tumour exosome integrins may be good biomarkers to predict organ-specific cancer metastasis (Hoshino et al, 2015) . Thus, further studies are needed to determine the cancer molecular networks associated with integrins.
CONCLUSIONS
Downregulation of dual-stranded miR-199 family members (miR199a-3p/-5p and miR-199b-3p/-5p) was frequently observed in BC cells, and these miRNAs significantly inhibited cancer cell migration and invasion. To the best of our knowledge, this is the first report demonstrating that tumour-suppressive miR-199a-3p/-5p and miR-199b-3p/-5p directly regulated ITGA3 and may be good prognostic markers for survival in patients with BC. The discovery of molecular targets mediated by tumour-suppressive miRNAs provides important insights into potential mechanisms, new therapeutics, and new biomarkers in BC.
